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Abstract
Based on the results of the TRANSITION and PIONEER-HF trials, the Heart Failure Association of the European Society 
of Cardiology has reported an expert consensus in 2019 that the initiation of sacubitril/valsartan, rather than an an-
giotensin-converting enzyme (ACE) inhibitor or an angiotensin II type 1 receptor blocker, may be considered for patients 
hospitalised with new-onset heart failure with reduced ejection fraction (HFrEF) or decompensated chronic HFrEF to 
reduce the short-term risk of adverse events and to simplify management by avoiding the need to titrate ACE inhibitors 
first, and then switch to an angiotensin receptor neprilysin inhibitor (ARNI). This paper describes the new data from the 
two trials, TRANSITION and PIONEER-HF.
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Since the announcement in 2016 of the latest guidelines 
of the European Society of Cardiology (ESC) on heart failure 
(HF), new data has emerged from subsequent studies using 
the drug sacubitril/valsartan, indicating the clinical benefits 
of this drug in an ever-wider population of patients in heart 
failure with reduced ejection fraction (HFrEF).
The TRANSITION study is a multi-centre, randomised, 
open-label, parallel-group study that compares two stra-
tegies of treatment with sacubitril/valsartan in patients 
with HFrEF who were hospitalised due to acute heart 
failure (AHF) [1].
The purpose of this study was to demonstrate the 
safety of sacubitril/valsartan and the tolerance of early 
incorporation of the drug in patients hospitalised owing to 
acute HFrEF who were stabilised haemodynamically. The 
study included patients with pre-existing or newly diagnosed 
(de novo) HF.
The study was conducted among patients taking an 
angiotensin-converting enzyme (ACE) inhibitor or an angio-
tensin II type 1 receptor blocker (ARB) at any dose before 
admission to hospital or patients who were previously not 
treated with an ACE inhibitor/ARB.
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Two strategies for initiating sacubitril/valsartan treat-
ment were evaluated:
 — at least 12 hours before discharge from hospital (pre-
discharge) and
 — 1–14 days after discharge from hospital (postdischarge).
The primary endpoint was reaching the target dose of 
sacubitril/valsartan at 97/103 mg twice a day during week 
10 after randomisation in groups in which the treatment 
was initiated prior to discharge and after discharge from 
the hospital.
Secondary endpoints were:
 — reaching and maintaining a dose of sacubitril/valsartan 
at 49/51 mg or 97/103 mg dose twice a day for at le-
ast two weeks leading to week 10 after randomisation 
(irrespective of any earlier temporary discontinuation of 
the treatment or dose reduction during the treatment 
period);
 — reaching and maintaining any dose of sacubitril/val-
sartan for at least two weeks leading to week 10 after 
randomisation;
 — permanent discontinuation of sacubitril/valsartan due 
to adverse reactions over a 10-week follow-up period.
The characteristics of the TRANSITION study population 
are shown in Table 2.
Primary and secondary dose endpoints were achieved 
in a comparable percentage of patients whose treatment 
was initiated before and after discharge, regardless of treat-
ment prior to hospitalisation (ACE inhibitor or ARB, with no 
ACE inhibitor/ARB treatment). About half of HFrEF patients 
stabilised after an AHF episode reached a target dose of 
Table 1. Inclusion criteria for the TRANSITION study (source [1])
Men or women aged ≥ 18
Hospitalised due to an episode of AHF recognised as the pri-
mary diagnosis
NYHA class II–IV HF diagnosis with reduced EF in screening 
tests
LVEF ≤ 40% in screening tests*
Patients who did not receive intravenous vasodilators (except 
nitrates) or intravenous inotropic drugs in the period between 
the occurrence of AHF and randomisation
Patients stabilised (during hospitalisation) for ≥ 24 h, meeting 
the following criteria:
• no need for intravenous use of diuretics in the last 24 h
• SBP ≥ 110 mm Hg from ≥ 6 h prior to randomisation
Meeting one of the following criteria:
• taking an ACE inhibitor or an ARB at any dose before be-
ing admitted to hospital
• patients previously not treated with an ACE inhibitor/ARB 
or not treated with an ACE inhibitor/ARB during ≥ 4 weeks 
prior to admission
*If not screened, EF ≤ 40% in any measurement taken locally over the last 12 months; AHF — 
acute heart failure; HF — heart failure; NYHA — New York Heart Association; EF — ejection fraction; 
LVEF — left ventricular ejection fraction; SBP — systolic blood pressure; ACE — angiotensin-conver-
ting enzyme; ARB — angiotensin II type 1 receptor blocker
Table 2. Characteristics of the TRANSITION study population (source [1])
Assessed parameters Before discharge 
N = 497
After discharge 
N = 496
Total 
N = 993
Age (average) [years] 66.7 66.9 66.8
Male, N [%] 372 (74.8) 373 (75.2) 745 (75.0)
Caucasian, N [%] 484 (97.4) 480 (96.8) 964 (97.1)
BMI [kg/m2], median 
(min–max)
27.9 
(17.6–58.8)
28.8 
(17.1–80.9)
28.4 
(17.1–80.9)
LVEF [%], mean ± SD 28.63 ± 7.49 28.94 ± 7.62 28.79 ± 7.55
Class according to NYHA
Class I, N [%] 0 (0.0) 3 (0.6) 3 (0.3)
Class II, N [%] 321 (64.6) 315 (63.5) 636 (64.0)
Class III, N [%] 167 (33.6) 172 (34.7) 339 (34.1)
Class IV, N [%] 7 (1.4) 5 (1.0) 12 (1.2)
SBP [mm Hg], mean ± SD 124 ± 13.7 124 ± 14.1 124 ± 13.9
eGFR [ml/min/1.73 m2], mean ± SD 62 ± 20.5 62 ± 19.4 62 ± 20.0
HF with ischaemic aetiology, N [%] 219 (44.1) 239 (48.2) 458 (46.1)
N — number of patients; BMI — body mass index; LVEF — left ventricular ejection fraction; SD — standard deviation; NYHA — New York Heart Association; SBP — systolic blood pressure; eGFR — estimated 
glomerular filtration rate; HF — heart failure
The inclusion criteria for the TRANSITION study are 
presented in Table 1.
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97/103 mg of sacubitril/valsartan two times/day during 
week 10. More than 86% of the patients in both groups 
took any dose of the drug for two weeks or more without 
any discontinuation of the treatment during 10 weeks of 
observation.
The drug was well tolerated; hypotension was the 
most common adverse reaction, which occurred in 12.1% 
of patients subjected to the predischarge strategy and 
9% of patients subjected to the postdischarge strategy 
(p = 0.123). Due to adverse reactions, treatment was per-
manently discontinued in 7.3% of patients and 4.9% in the 
pre- and postdischarge groups, respectively (p = 0.117).
The TRANSITION study documented that the initiation 
of sacubitril/valsartan soon after an AHF episode during 
hospitalisation or shortly after discharge from hospital 
was feasible and well tolerated in a wide population of 
patients with HFrEF.
In the TRANSITION study, among the patients starting 
treatment with sacubitril/valsartan predischarge, a signi-
ficant 28% reduction in the concentration of N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) was found as 
geometric mean ratio at the time of discharge compared 
to the starting point [0.718, 95% confidence interval (CI): 
0.677–0.762, p < 0.0001] [2]. In contrast, in the group 
of postdischarge patients, who were initially treated with 
standard therapy drugs in HFrEF, there were no significant 
changes in the NT-proBNP concentration (GMR 0.966, 
95% CI: 0.905–1.031, p = 0.293). At the time of discharge 
from the hospital, the difference between the analysed 
groups of patients (predischarge vs. postdischarge) was 
statistically significant in terms of the NT-proBNP concen-
tration (p < 0.001). The use of sacubitril/valsartan during 
hospitalisation was also associated with a significant re-
duction in the levels of high-sensitivity troponin T (hsTnT) 
from the starting point to discharge from the hospital for 
predischarge patients, but not for postdischarge patients 
on a standard HFrEF treatment. A further decrease from 
the starting point was found in both examined groups for 
both biomarkers in weeks 4 and 10 with no significant dif-
ferences between the predischarge versus postdischarge 
groups [2].
The initiation of predischarge treatment with sacubitril/ 
/valsartan in patients hospitalised due to AHF after achie-
ving haemodynamic stability is associated with early and 
long-term improvement in biomarkers of cardiac wall stress 
and myocardial damage, indicating pathophysiological 
benefits in a wide group of people with HFrEF.
PIONEER-HF is another study using sacubitril/valsartan 
in a population of patients with AHF [3]. The most important 
criteria for inclusion in the study were:
 — hospitalisation due to AHF (de novo about 1/3 of the 
population, 2/3 of the population exacerbation of 
chronic HF);
 — LVEF not exceeding 40% in the last six months;
 — concentration of NT-proBNP not less than 1,600 pg/mL 
or B-type natriuretic peptide (BNP) not less than 
400 pg/mL;
 — haemodynamic stabilisation during hospitalisation 
defined as:
• systolic blood pressure (SBP) greater than or equal 
to 100 mm Hg in the last six hours; without symp-
tomatic hypotension,
• no increase in the dose of intravenous diuretics in 
the last six hours,
• no use of any intravenous vasodilators in the last 
six hours,
• not use of any intravenous inotropic drugs in the 
last 24 hours.
The characteristics of the population are shown in 
Table 3.
Table 3. Characteristics of the PIONEER-HF study population (source [3])
Assessed parameters Sacubitril/valsartan 
(N = 440)
Enalapril 
(N = 441)
Age [years] 61 (50.5–71) 63 (54–72)
Women [%] 25.7 30.2
African origin [%] 35.9 35.8
Prior HF diagnosis [%] 67.7 63.0
LVEF [%], median (25., 75.) 24 (18–30) 25 (20–30)
Systolic blood pressure, median (25., 75.) [mm Hg] 118 (110–133) 118 (109–132)
NT-proBNP concentrations, median (25., 75.) [pg/mL]  
at the time of randomisation
2,883 (1,610–5,403) 2,536 (1,363–4,917)
ACE inhibitor/ARB treatment [%] 47.3 48.5
Drugs blocking beta-adrenoreceptor activity [%] 59.6 59.6
N — number of patients; HF — heart failure; LVEF — left ventricular ejection fraction; ACE — angiotensin-converting enzyme; NT-proBNP — N-terminal pro-B-type natriuretic peptide; ARB — angiotensin II type 1 
receptor blocker
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The comparator in this study, as in the PARADIGM-HF 
trial, was 10 mg enalapril administered twice a day. The 
follow-up comprised eight weeks.
The PIONEER-HF study evaluated:
 — the primary endpoint — time-averaged proportional 
change in the concentration of NT-proBNP from the 
starting point to weeks 4 and 8;
 — treatment safety:
• worsening of kidney function,
• hyperkalemia,
• symptomatic hypotension,
• angioedema;
 — exploratory clinical evaluation measures: composi-
te endpoint including major clinical events: death, 
hospitalisation due to HF, the need to implant a left 
ventricular assist device (LVAD) or listing for a heart 
transplant.
During the eight weeks of observation, early and sig-
nificantly greater reductions in NT-proBNP (Figure 1), and 
a reduction of endpoints of serious clinical events compa-
red to patients treated with enalapril were documented 
in the case of patients treated with sacubitril/valsartan 
(Figure 2) [3].
The drug was well tolerated; among the most common 
adverse reactions were symptomatic hypotension (15% 
of patients treated with sacubitril/valsartan vs. 12.7% of 
patients treated with enalapril), worsening of renal function 
(13.6% of patients treated with sacubitril/valsartan vs. 
14.7% of patients treated with enalapril), and hyperka-
lemia (11.6% of those treated with sacubitril/valsartan 
vs. 9.6% of those treated with enalapril) and episodes of 
angioedema in individual patients (0.2% of those treated 
with sacubitril/valsartan vs. 1.4% of those treated with 
enalapril).
It is safe to initiate predischarge treatment with sacu-
bitril/valsartan in patients hospitalised due to AHF after 
reaching haemodynamic stabilisation. It has a positive 
effect on lowering biomarkers of cardiac wall tension and 
it reduces the risk of serious clinical events.
Despite the limitations of both studies, which were 
discussed in the original publications, the results of the 
TRANSITION and PIONEER-HF studies provide the basis for 
extending the use of sacubitril/valsartan in HFrEF.
Conclusion
The results of the TRANSITION and PIONEER-HF studies 
documented the benefits of initiating treatment with sacu-
bitril/valsartan in patients with HFrEF in the predischarge 
period due to AHF. The predischarge period and the first few 
months after the end of hospitalisation due to AHF belong 
to the vulnerable phase. The vulnerable phase is charac-
terised by a high risk of death, prehospitalisation owing to 
HF exacerbations and excessive neurohormonal activation 
[4, 5]. According to the study protocols, to initiate treat-
ment with sacubitril/valsartan it is necessary to achieve 
haemodynamic stability of a patient during hospitalisa-
tion, i.e. for at least six hours without the administration 
of intravenous diuretics and vasodilators, and 24 hours 
without the administration of intravenous inotropic drugs, 
with an additional SBP of at least 100 mm Hg without any 
symptomatic hypotension.
Figure 1. Results of the PIONEER-HF study in terms of the primary endpoint (based on [3]); *percentage (%) change from the starting point 
to the mean value during weeks 4 and 8; NT-proBNP — N-terminal pro-B-type natriuretic peptide; HR — hazard ratio; CI — confidence interval
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The results of the TRANSITION and PIONEER-HF studies 
were included in the expert report of the Association of 
Heart Failure ESC in 2019 [6], which indicates that the 
initiation of treatment with sacubitril/valsartan can be 
considered instead of an ACE inhibitor or ARB in patients 
hospitalised due to acute HF symptoms (de novo or exacer-
bation of chronic HF) to improve prognosis in the short term 
and facilitate treatment [avoiding ACE inhibitor treatment 
with the principle of increasing doses and switching to an 
AT1 receptor antagonist for angiotensin II and a neprilysin 
inhibitor (ARNI)].
Initiating treatment with sacubitril/valsartan does not 
require NT-proBNP to be tested, because the patient in the 
predischarge period is at high risk of cardiovascular events.
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Streszczenie
Stanowisko eksperckie Asocjacji Niewydolności Serca Europejskiego Towarzystwa Kardiologicznego z 2019 roku wska-
zuje, że rozpoczęcie terapii lekiem sakubitril/walsartan można rozważyć zamiast inhibitora konwertazy angiotensyny 
(ACE) czy antagonisty receptora AT1 dla angiotensyny II u chorych hospitalizowanych z powodu ostrej niewydolności ser-
ca z obniżoną frakcją wyrzutową (HFrEF) (de novo lub zaostrzenia przewlekłej HF) w celu poprawy rokowania w okresie 
krótkoterminowym i ułatwienia prowadzenia leczenia (uniknięcie leczenia inhibitorem ACE z zasadą zwiększania dawek 
i zamiany na antagonistę receptora AT1 dla angiotensyny II i inhibitora neprylizyny [ARNI]). Stanowisko to opiera się na 
wynikach dwóch opublikowanych badań — TRANSITION oraz PIONEER-HF. W poniższym artykule przedstawiono dane 
z tych badań.
Słowa kluczowe: sakubitril/walsartan, ostra niewydolność serca, HFrEF, okres przedwypisowy
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Figure 2. Results of the PIONEER-HF study in the exploratory composite endpoint (based on [3]); *the incidence of the exploratory endpoint, 
including major clinical events, were associated with a reduction in the risk of death and the frequency of re-hospitalisations due to heart 
failure (HF); LVAD — left ventricular assist device; HR — hazard ratio; CI — confidence interval; NNT — number needed to treat; N — number 
of patients
521www.journals.viamedica.pl/folia_cardiologica
Małgorzata Lelonek, Sakubitril/walsartan in acute HFrEF
References
1. Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. 
Initiation of sacubitril/valsartan in haemodynamically stabilised heart 
failure patients in hospital or early after discharge: primary results 
of the randomised TRANSITION study. Eur J Heart Fail. 2019; 21(8): 
998–1007, doi: 10.1002/ejhf.1498, indexed in Pubmed: 31134724.
2. Pascual-Figal D, Senni M, Belohlavek J, et al. Short-term effect on 
cardiac biomarkers of initiation of sacubitril/valsartan in hospitalized 
patients with heart failure and reduced ejection fraction: results of 
the TRANSITION study. Poster [Su2183] presented at AHA Congress 
2018, Chicago, USA.
3. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investiga-
tors. Angiotensin-neprilysin inhibition in acute decompensated heart 
failure. N Engl J Med. 2019; 380(6): 539–548, doi: 10.1056/NEJ-
Moa1812851, indexed in Pubmed: 30415601.
4. Matyjas K, Lelonek M. Pacjent z niewydolnością serca w okresie 
vulnerable phase. Folia Cardiol. 2018; 13(1): 71–78, doi: 10.5603/ 
/fc.2018.0014.
5. Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnera-
ble phase after hospitalization for heart failure. Nat Rev Cardiol. 
2015; 12(4): 220–229, doi: 10.1038/nrcardio.2015.14, indexed in 
Pubmed: 25666406.
6. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update 
on heart failure 2019: pharmacotherapy, procedures, devices and pa-
tient management. An expert consensus meeting report of the Heart 
Failure Association of the European Society of Cardiology. Eur J Heart 
Fail. 2019 [Epub ahead of print], doi: 10.1002/ejhf.1531, indexed in 
Pubmed: 31129923.
